Fabhalta Capsule
NDC 0078-1189
Product Information
Fabhalta (iptacopan) is a NDA-approved product labeled by Novartis Pharmaceuticals Corporation. This medication is typically used as a complement factor b inhibitor [epc]. It is supplied as a yellow capsule for oral administration. This product entry covers the primary NDC 0078-1189 and its associated package configuration. This profile includes active and inactive ingredient UNII references and FDA labeling data.
Primary Identification
Clinical Specifications
Labeler & Regulatory Data
Marketing Timeline
Product Characteristics
LNP200;NVR
Code Structure Chart
Product Details
What is NDC 0078-1189?
What are the uses of this product?
What are Active Ingredients of this product?
Which are the associated UNII Codes?
The UNII codes for the active ingredients in this product are:
- IPTACOPAN HYDROCHLORIDE (UNII: XW5CK7C6YH)
- IPTACOPAN (UNII: 8E05T07Z6W) (Active Moiety)
Which are the Inactive Ingredients associated UNII Codes?
The inactive ingredients are all the component of a medicinal product OTHER than the active ingredient(s). The acronym "UNII" stands for “Unique Ingredient Identifier” and is used to identify each inactive ingredient present in a product. The UNII codes for the inactive ingredients in this product are:
- FERROSOFERRIC OXIDE (UNII: XM0M87F357)
- GELATIN (UNII: 2G86QN327L)
- POTASSIUM HYDROXIDE (UNII: WZH3C48M4T)
- PROPYLENE GLYCOL (UNII: 6DC9Q167V3)
- FERRIC OXIDE RED (UNII: 1K09F3G675)
- SHELLAC (UNII: 46N107B71O)
- AMMONIA (UNII: 5138Q19F1X)
- TITANIUM DIOXIDE (UNII: 15FIX9V2JP)
- FERRIC OXIDE YELLOW (UNII: EX438O2MRT)
What is the NDC to RxNorm Crosswalk for this product?
- RxCUI: 2671074 - iptacopan 200 MG Oral Capsule
- RxCUI: 2671074 - iptacopan 200 MG (as iptacopan hydrochloride 225.8 MG) Oral Capsule
- RxCUI: 2671080 - FABHALTA 200 MG Oral Capsule
- RxCUI: 2671080 - iptacopan 200 MG Oral Capsule [Fabhalta]
- RxCUI: 2671080 - Fabhalta 200 MG (as iptacopan hydrochloride 225.8 MG) Oral Capsule
Which are the Pharmacologic Classes of this product?
* Please review the full disclaimer at the bottom of this page.